Next Article in Journal
Breast Cancer: Surgery at the South Egypt Cancer Institute
Next Article in Special Issue
The Enigmatic Roles of Caspases in Tumor Development
Open AccessReview

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs

Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan
Department of Pathology, Tohoku University Hospital, Sendai, Japan
Computational Biology Research Center, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan
Author to whom correspondence should be addressed.
Cancers 2010, 2(3), 1717-1730;
Received: 23 August 2010 / Revised: 14 September 2010 / Accepted: 15 September 2010 / Published: 17 September 2010
(This article belongs to the Special Issue Cell Death and Cancer)
5-Fluorouracil (5-FU) is a key anticancer drug that for its broad antitumor activity, as well as for its synergism with other anticancer drugs, has been used to treat various types of malignancies. In chemotherapeutic regimens, 5-FU has been combined with oxaliplatin, irinotecan and other drugs as a continuous intravenous infusion. Recent clinical chemotherapy studies have shown that several of the regimens with oral 5-FU drugs are not inferior compared to those involving continuous 5-FU infusion chemotherapy, and it is probable that in some regimens continuous 5-FU infusion can be replaced by oral 5-FU drugs. Historically, both the pharmaceutical industry and academia in Japan have been involved in the development of oral 5-FU drugs, and this review will focus on the current knowledge of 5-FU anabolism and catabolism, and the available information about the various orally-administrable 5-FU drugs, including UFT, S-1 and capecitabine. Clinical studies comparing the efficacy and adverse events of S-1 and capecitabine have been reported, and the accumulated results should be utilized to optimize the treatment of cancer patients. On the other hand, it is essential to elucidate the pharmacokinetic mechanism of each of the newly-developed drugs, to correctly select the drugs for each patient in the clinical setting, and to further develop optimized drug derivatives. View Full-Text
Keywords: 5-FU metabolism; cell death; colon cancer; oral 5-FU drugs 5-FU metabolism; cell death; colon cancer; oral 5-FU drugs
Show Figures

Figure 1

MDPI and ACS Style

Miura, K.; Kinouchi, M.; Ishida, K.; Fujibuchi, W.; Naitoh, T.; Ogawa, H.; Ando, T.; Yazaki, N.; Watanabe, K.; Haneda, S.; Shibata, C.; Sasaki, I. 5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs. Cancers 2010, 2, 1717-1730.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop